Mar. 23 -- FRIDAY, June 22 (HealthDay News) -- A drug derived from the sea squirt showed anti-tumor activity in more than half of 51 patients with a type of cancer called advanced pretreated myxoid ...
From May 2011 to June 2020, 101 patients with HG-MLPS were randomly assigned, 45 to the HT arm and 56 to the S arm. The median follow-up was 66 months (IQR, 37-89). Median size was 107 mm (IQR, 84-143 ...
Overall response rate of 40% consistent across sarcoma indications; median duration of response ~11 months with patients still in response at time of analysis Interim analysis data reinforces the ...
Afami-cel, sold as Tecelra by Adaptimmune, is the first gene therapy to be approved for the rare form of cancer and the first FDA-approved T-cell receptor gene therapy. The accelerated approval was ...
Patients with advanced synovial sarcoma may have a new therapy option if the novel drug, afami-cel, is approved by the FDA after the priority review. The Food and Drug Administration (FDA) has ...
A rare form of cancer is gaining awareness and important research funding thanks to a nationwide and global event that started here in the Capital Region. the 11th annual Sarcoma Strong 5K brought ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback